Post-earnings recap
Reported
Thu, Mar 3, 2011
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a larger-than-expected loss per share, which contributed to a 1.44% decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's future performance. Overall, the results indicate ongoing challenges that the company needs to address moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.24 | N/A | -214.29% |
| Revenue | N/A | N/A | N/A |
Management's tone was cautious as they addressed the company's performance. They highlighted ongoing challenges but did not provide specific future guidance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in meeting EPS expectations.